TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03971487: Ocrelizumab for Psychosis by Autoimmunity

Sponsor: The Methodist Hospital Research Institute · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,553,600

Rescue Site Savings

+$6,958,780

Unlock Full NCT03971487 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03971487 Rescue Dossier →